-
'I want to be Eala': Philippine sensation sparks tennis boom at home
-
Australia probes three near-misses at Sydney Airport
-
US says lower oil prices, not Iran's nuclear program, are now top priority in war
-
Classy Tanzid puts Bangladesh in firm charge against Australia
-
Most Asian stocks track Wall St record as US data ease rate fears
-
Schwarber smacks two homers to power Philles' MLB Field of Dreams win
-
China's viral 'spicy strips' take a bite of global snack market
-
Pakistan's date workers toil through rising heat
-
Shelton does the double in Canada
-
New trend of injecting banned peptides to 'optimise' body
-
'Shock' gloves for US immigration agents fuel potential abuse fears
-
Eddie Jones senses Japan's time has come against Australia
-
New Zealand Football withdraws support for Infantino, urges review
-
UK vote count under way in Farage, Binface showdown
-
Hopes fade in Colombia as window to find quake survivors shuts
-
US, Mexico conduct security exercises near border
-
Trump announces tariffs of up to 100% on imported drones
-
Swiatek rolls past Rybakina for WTA Toronto title
-
Spieth among five sharing Memphis lead as PGA playoffs open
-
Vance says low oil prices are top US goal in Iran conflict
-
Boats rescue tourists as forest fire flames threaten Greek beaches
-
Hunt bags Euro sprint double, Ceh keeps discus title
-
Good vibes powering Djokovic return to Cincinnati
-
'Dream come true': Owners reunite with pets in quake-hit Colombia
-
Britain's Hunt wins 200m for European sprint double
-
US stocks gain after benign inflation data, oil prices retreat
-
Draper dumped as Norrie saves face for Britain in Cincinnati
-
LeBron's Sixers in spotlight as full 2026-27 NBA schedule revealed
-
England opener Gay out for duck in Pakistan warm-up
-
Kennedy Center board votes to restore Trump name: reports
-
Europe swelters under fresh wave of extreme heat
-
Barcelona agree to sell Torres to PSG: media
-
French Olympic gold medallist Florent Manaudou announces retirement
-
Romania shuts nuclear plant as Danube drops
-
Tourists rescued by boat as forest fire threatens Greek beaches
-
Millions of Europeans struggle with another wave of extreme heat
-
Indicted Raul Castro reappears after months out of public view
-
Israel reopens once-closed West Bank settlement
-
Italian teen Curtis breaks women's 50m backstroke world record for second time
-
Taylor to captain New Zealand for first time against Bulls
-
Taulagi steps out of 'comfort zone' with code switch to French Top 14 new boys
-
Carrick urges Man Utd to push for more signings to boost title bid
-
Leicester's Thai owners put troubled club up for sale: reports
-
'This was my World Cup' says Somali ref after UEFA Super Cup
-
Stocks steady as US inflation worries ease, oil slips
-
Survivors tell of horror of Zimbabwe ferry sinking as death toll hits 46
-
Porsche to end production of flagship electric car: report
-
Juventus forward Vlahovic signs three-year Besiktas deal
-
Twitch sparks gamers' wrath with Amazon AI sharing deal
-
Tielemans apologises for offending Villa fans with Man Utd boast
Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
X.AbuJaber--SF-PST